Disease · MONDO_0100491
generalized pustular psoriasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. generalized pustular psoriasis. Diseases, record MONDO_0100491. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100491
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 8 of its 11 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SPESOLIMAB | CHEMBL4297911 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| IMSIDOLIMAB | CHEMBL4650441 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| RISANKIZUMAB | CHEMBL3990029 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ADALIMUMAB | CHEMBL1201580 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GUSELKUMAB | CHEMBL2364648 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ICOTROKINRA | CHEMBL6068124 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ZASOCITINIB | CHEMBL5314423 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEUCRAVACITINIB | CHEMBL4435170 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL12B | Interleukin-12 | 3 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Phase 3 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 3 | Interleukin-23 inhibitor | Phase 3 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| IL1RAP | IL36 receptor | 2 | IL36 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3556 | Drugs and targets |
| IL36R | IL36 receptor | 2 | IL36 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/8808 | Drugs and targets |
| IL12A | Interleukin-12 | 1 | Interleukin-12 inhibitor | Unknown | https://conductscience.org/library/genes/3592 | Drugs and targets |
| IL17A | Interleukin-17A | 1 | Interleukin 17A inhibitor | Phase 3 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| TNF | Tumor necrosis factor | 1 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| TYK2 | Non-receptor tyrosine-protein kinase TYK2 | 1 | Tyrosine-protein kinase TYK2 negative allosteric modulator | Unknown | https://conductscience.org/library/genes/7297 | Drugs and targets |
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02672852 | BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment | Phase 3 | 507 | 2019-05-28 | Psoriasis | RISANKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03782792 | Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis | Phase 2 | 53 | 2022-03-09 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05352893 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | Phase 3 | 45 | 2026-03-17 | Generalized Pustular Psoriasis | IMSIDOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05239039 | An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | Phase 3 | 39 | 2024-10-09 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01794117 | Anakinra for Inflammatory Pustular Skin Diseases | Phase 2 | 18 | 2021-04-30 | Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
| NCT03022045 | A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Phase 3 | 18 | 2019-02-06 | Psoriasis | RISANKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01952015 | Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | Phase 3 | 12 | 2019-03-15 | Psoriasis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05200247 | An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | Phase 3 | 11 | 2024-08-15 | Generalized Pustular Psoriasis | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02533375 | Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | Phase 3 | 10 | 2019-01-14 | Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03619902 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis | Phase 2 | 8 | 2022-03-29 | Generalized Pustular Psoriasis | IMSIDOLIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Spesolimab 900 mg i.v SD vs Placebo: Number of Patients With Treatment Emergent Adverse Events (TEAEs) Within the Treatment Phase | 29 of 35 | 13 of 18 | 53 | NCT03782792 | Trial comparisons |
| Spesolimab 900 mg i.v SD vs Placebo: Number of Patients With Treatment Emergent Adverse Events (TEAEs) up to Week 1 | 27 of 35 | 12 of 18 | 53 | NCT03782792 | Trial comparisons |
| Spesolimab Single Dose Treatment vs Spesolimab Double Dose Treatment: Occurrence of Treatment Emergent Adverse Events (AEs) | 18 of 24 | 12 of 15 | 39 | NCT05239039 | Trial comparisons |
| Spesolimab Single Dose Treatment vs Spesolimab Double Dose Treatment: Occurrence of Treatment Emergent Adverse Events of Special Interest (AESIs) | 1 of 24 | 1 of 15 | 39 | NCT05239039 | Trial comparisons |
| Spesolimab Single Dose Treatment vs Spesolimab Double Dose Treatment: Occurrence of Treatment Emergent Serious Adverse Events (SAEs) | 1 of 24 | 2 of 15 | 39 | NCT05239039 | Trial comparisons |
| Spesolimab Single Dose Treatment vs Spesolimab Double Dose Treatment: deaths from any cause | 0 of 24 | 0 of 15 | 39 | NCT05239039 | Trial comparisons |
| Spesolimab Single Dose Treatment vs Spesolimab Double Dose Treatment: serious adverse events | 1 of 24 | 2 of 15 | 39 | NCT05239039 | Trial comparisons |
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100491
GET https://conductscience.org/api/diseases/v1/MONDO_0100491/drugs